In a phase 2 trial, OCU410, a modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration, ...
Randomized trials of two FDA-approved intravitreal complement inhibitor injections showed that they slowed the progression of geographic atrophy, but failed to demonstrate functional benefits at 24 ...
Please provide your email address to receive an email when new articles are posted on . CTx001 is an investigational adeno-associated virus-based therapy for geographic atrophy. Patient dosing in the ...
Intravitreal complement inhibitor injections (IVCIs) for geographic atrophy appeared to be acceptable to most patients if they assumed the treatment had functional vision benefits, a cross-sectional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results